4
Changes in Ownership
Edgewise Therapeutics, Inc. Filed Acc 0001209191-21-023867
Director bought 359,375 shares at $16.00 ($5,750,000)
- Director acquired 13,002,760 shares (conversion)
From the SEC's structured data for this filing
Trades in this filing
ORBIMED ADVISORS LLC · Director
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-03-30 | Conversion : show line 1 in the form | +12,730,036 | 13,046,956 | I | ||
| 2021-03-30 | Conversion : show line 2 in the form | +272,724 | 272,724 | I | ||
| 2021-03-30 | Purchase : show line 3 in the form | +46,875 | $16.00 | $750,000 | 319,599 | I |
| 2021-03-30 | Purchase : show line 4 in the form | +312,500 | $16.00 | $5,000,000 | 13,359,456 | I |
| Open-market purchases · 359,375 sh · avg $16.00 · $5,750,000 | ||||||
Table II: Derivative
5 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2021-03-30 | Conversion : show line 5 in the form Series A Preferred Stock | −8,187,100 | 0 | I |
| 2021-03-30 | Conversion : show line 6 in the form Series B-1 Preferred Stock | −1,572,960 | 0 | I |
| 2021-03-30 | Conversion : show line 7 in the form Series B-2 Preferred Stock | −1,301,626 | 0 | I |
| 2021-03-30 | Conversion : show line 8 in the form Series C Preferred Stock | −1,668,350 | 0 | I |
| 2021-03-30 | Conversion : show line 9 in the form Series C Preferred Stock | −272,724 | 0 | I |
Loading xslF345X03/doc4.xml…